NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: AnaSpec, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3 - AnaSpec, EGT Group is pleased to offer Eurogentec’s popular monoclonal antibody, anti-5-methylcytidine (Clone 33D3) for use in epigenetics research - AnaSpec.com
AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/05/29 - AnaSpec, EGT Group is pleased to offer Eurogentec’s popular monoclonal antibody, anti-5-methylcytidine (Clone 33D3) for use in epigenetics research - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Purified from ascites, this IgG1 / λ isotype antibody is supplied as a 1 mg/ml solution (in PBS) and is available in three sizes (0.1 mg, 0.5 mg and 1 mg).
5-Methylcytidine (5-MeCyd) is cytosine modified by methylation on the fifth position of the cytidine ring. This modification occurs naturally in the DNA of plants and vertebrate. DNA methylation is a post-replication process involved in the establishment of genomic imprinting, in the control of gene expression and of differentiation. Alterations of DNA methylation pattern are associated with carcinogenesis. A global DNA hypomethylation is often detected in tumor tissues, associated with local hypermethylation sites. Since this antibody discriminates between the modified base, 5-MeCyd and its normal counterpart, cytosine, it is a useful tool for gene promoter methylation analysis.

The most published anti-5-Methylcytidine antibody available on the market, anti-5-Methylcyidine from Clone 33D3 can be used in applications such as Methylated DNA Immunoprecipitation (MeDIP), MeDIP-on-chip assay, immunofluorescence, flow cytometry and immunohistochemistry. Histopathological analysis of tissue samples can be performed without having to destroy cells through DNA extraction procedures.

This antibody has been used to detect alterations in the urinary excretion of nucleosides from cancer patients, to visualize the distribution of methyl-rich regions along human chromosomes, to quantify in situ differences between normal and malignant cells from peripheral blood as well as on tissue sections.

AnaSpec, EGT Group

AnaSpec, Eurogentec Group (anaspec.com) is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering
DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
Veeva Widely Recognized for Leadership and Innovation in Support of Customers and Employees
Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management
Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow, Inc.





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)